Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donafenib + toripalimab for advanced biliary tract cancer in patients refusing chemotherapy
ChiCTR2100050060Phase 4Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Aug 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of donafenib and toripalimab in biliary cancer (2 cohorts), sponsored by Peking Union Medical College Hospital. Primary endpoint: Progression-free survival. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
donafenibtoripalimab
03
Conditions
biliary cancer
Beyond the preview
Go deeper on ChiCTR2100050060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050060.